SHARE’s Annual Volunteer Party

April is National Volunteer Appreciation Month, and SHARE hosted its annual volunteer party to show how much we appreciate the incredible commitment of our volunteers. It was another great gathering with a raffle, food, music, and of course, amazing company.

Victoria: Living with HER2+ Metastatic Breast Cancer

Victoria: Living with HER2+ Metastatic Breast Cancer

My original cancer diagnosis was on Valentine’s Day of 2005.  I was 44 years old, had a busy career, a husband and two young sons.  During a routine gynecological exam my doctor found a small lump in my right breast. Subsequent tests confirmed a 1 cm invasive ductal carcinoma.

Announcing SHARE’s National Expansion

New Support Groups Active in Norwalk, CT; Brentwood, NY; and Orlando, FL
After 42 years in New York City, SHARE Cancer Support has announced a national expansion effort. Norwalk, CT; Brentwood, Long Island, NY; and Orlando, FL are the first cities outside New York City to offer SHARE’s in-person services to women with breast or ovarian cancers.

Introducing new program formats!

If you receive our program calendar or email newsletter, you may have noticed some new types of educational programs. In addition to our webinars and in-person programs, we are now offering interactive educational opportunities through other platforms. These new kinds of programs offer the same quality content, and make it easy for you to engage with the presenters.

Treating Endocrine-Resistant Metastatic Breast Cancer

In September, the FDA approved amebaciclib (Verzenio), the latest drug to treat endocrine resistant metastatic breast cancer (MBC). In combination with fulvestrant (Faslodex), the results of the phase III, Monarch 2 trial showed an improvement in progression free survival (PFS). All the patients in the trial were hormone receptor positive and HER2 negative, as are all the enrollees in the trials noted here.

Update on TAPUR Study

At its annual meeting this year in June, the American Society of Clinical Oncology (ASCO) gave patient advocates an update on the TAPUR clinical trial, which is its first trial. The trial was rolled out about two years ago.

The TAPUR trial (Targeted Agent and Profiling Utilization Registry) allows us to obtain FDA-approved drugs free-of-charge by cutting out the red tape when we are no longer benefiting from any standard treatment.

National Helpline:
844-ASK-SHARE